rDEN2Δ30-7169
Phase 1Biologic
rDEN2Δ30-7169 is one of 4 biologic programs targeting Infection. It is currently in Phase 1.
2
Indications
8
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Dengue
#DrugCompanyPhaseTrials
1Lagevrio
Merck & Co.Phase 2
rDEN2Δ30-7169
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
Biological
NNational Environment Agency, Singapore
Preclinical
Emetine Hydrochloride
JJohns Hopkins University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immune Response2 trials
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02392325·12 enrolled
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01931176·14 enrolled
Infection1 trial
Dengue1 trial
Safety and Efficacy1 trial
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02317900·48 enrolled
Effectiveness1 trial
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02021968·48 enrolled
2 more indications
Single Dose1 trial
Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rDEN2Δ30-7169. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details